Vericel (VCEL) Gross Profit (2011 - 2026)
Vericel (VCEL) posted Gross Profit of $56.4 million for Q2 2026, up 14.48% sequentially from $49.3 million in Q1 2026, and up 21.0% YoY from $46.6 million in Q2 2025.
Analysis
Vericel (VCEL) Gross Profit (2011 - 2026) Analysis & Trends
Vericel has reported Gross Profit for 16 years, with the latest figure at $56.4 million in Q2 2026.
- Quarterly Gross Profit rose 21.0% year-over-year to $56.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $228.4 million (up 24.77% YoY) and the FY2025 annual result came in at $205.6 million, up 19.46% from the prior year.
- Gross Profit climbed to $56.4 million in Q2 2026 per VCEL's latest filing, from $49.3 million in the prior quarter.
- Over five years, Gross Profit peaked at $73.1 million in Q4 2025 and troughed at $22.9 million in Q2 2022.
- A 5-year average of $40.5 million and a median of $37.4 million in 2022 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2022 and 2024: Gross Profit decreased 15.07% in 2022, then jumped 36.09% in 2024.
- Over 5 years, Gross Profit stood at $38.2 million in 2022, then rose by 26.82% to $48.5 million in 2023, then rose by 20.6% to $58.5 million in 2024, then grew by 25.01% to $73.1 million in 2025, then retreated by 22.87% to $56.4 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $56.4 million, $49.3 million, and $73.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.40 Mn |
| Mar 31, 2026 | 49.27 Mn |
| Dec 31, 2025 | 73.13 Mn |
| Sep 30, 2025 | 49.59 Mn |
| Jun 30, 2025 | 46.61 Mn |
| Mar 31, 2025 | 36.27 Mn |
| Dec 31, 2024 | 58.50 Mn |
| Sep 30, 2024 | 41.65 Mn |
| Jun 30, 2024 | 36.60 Mn |
| Mar 31, 2024 | 35.35 Mn |
| Dec 31, 2023 | 48.51 Mn |
| Sep 30, 2023 | 30.61 Mn |
| Jun 30, 2023 | 29.94 Mn |
| Mar 31, 2023 | 26.52 Mn |
| Dec 31, 2022 | 38.25 Mn |
| Sep 30, 2022 | 25.23 Mn |
| Jun 30, 2022 | 22.85 Mn |
| Mar 31, 2022 | 23.45 Mn |
| Dec 31, 2021 | 34.03 Mn |
| Sep 30, 2021 | 22.10 Mn |